Home
Live Updates
Opdivo Plus Chemo Did Not Improve Progression in EGFR-Mutated NSCLC : comparemela.com
Opdivo Plus Chemo Did Not Improve Progression in EGFR-Mutated NSCLC
Treatment with Opdivo (nivolumab) and chemotherapy did not significantly improve progression-free survival when compared with chemotherapy alone among some patients with EGFR-mutated metastatic non-small-cell lung cancer.
Related Keywords
United States ,
Taiwan ,
China ,
Japan ,
South Korea ,
Spain ,
France ,
Singapore ,
Tagrisso Osimertinib ,
Ching Kong ,
News ,
Lung Cancer ,
Non Small Cell Lung Cancer ,
Opdivo ,
Chemotherapy ,
comparemela.com © 2020. All Rights Reserved.